FibroBiologics (FBLG) Income from Continuing Operations (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Income from Continuing Operations of 5560000.0 for Q2 2026, up 26.41% year-over-year from 4398513.09 in Q2 2025, and up 26.44% on a QoQ basis from 7558000.0 in Q1 2026.
FibroBiologics (FBLG) Income from Continuing Operations (2023 - 2026) Analysis & Trends
FibroBiologics has reported Income from Continuing Operations for 4 years, with the latest figure at 5560000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 5560000.0, up 26.41% year-over-year; the trailing twelve-month figure through Jun 2026 was 23748000.0 (down 1.72% YoY), and the FY2025 annual result was 25634000.0, down 36.76% from the prior year.
- Income from Continuing Operations rose to 5560000.0 in Q2 2026, from 7558000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1907000.0 in Q3 2023 and troughed at 7866000.0 in Q3 2025.
- A 4-year average of 4478857.14 and a median of 3535000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2024, when Income from Continuing Operations slumped 230.15%; it then climbed 26.41% in 2026.
- A 4-year view of Income from Continuing Operations shows it stood at 2626000.0 in 2023, then plunged by 39.19% to 3655000.0 in 2024, then climbed by 24.38% to 2764000.0 in 2025, then tumbled by 101.16% to 5560000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 5560000.0 in Q2 2026, 7558000.0 in Q1 2026, and 2764000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.56 Mn |
| Mar 31, 2026 | -7.56 Mn |
| Dec 31, 2025 | -2.76 Mn |
| Sep 30, 2025 | -7.87 Mn |
| Jun 30, 2025 | -5.02 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Dec 31, 2024 | -3.66 Mn |
| Sep 30, 2024 | -6.30 Mn |
| Jun 30, 2024 | -3.16 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Dec 31, 2023 | -2.48 Mn |
| Sep 30, 2023 | -2.05 Mn |
| Jun 30, 2023 | -2.10 Mn |
| Mar 31, 2023 | -2.40 Mn |